InfuSystems (INFU) vs Profound Medical (PROF)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
InfuSystems (INFU) has outperformed Profound Medical (PROF) over the past year, gaining 51.7% versus a gain of 6.2%. Over five years, INFU leads with a -15.9% price change compared with -43.6% for PROF. InfuSystems is the larger company by market cap ($287.5 million vs $233.7 million), about 1.2 times the size, while Profound Medical is growing revenue faster (+50.7% vs +6.4%).
InfuSystems converts more of its revenue into profit, with a net margin of 4.6% versus -264.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INFU | PROF |
|---|---|---|
| Share price | $14.35 | $6.38 |
| Market cap | $287.48M | $233.68M |
| 1-day change | +2.06% | -3.19% |
| YTD return | +59.98% | -18.93% |
| 1-year return | +51.69% | +6.16% |
| 5-year return | -15.93% | -43.64% |
| P/E ratio (TTM) | 32.61 | — |
| Forward P/E | 25.63 | — |
| EPS (TTM) | $0.44 | $-0.94 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $143.44M | $16.10M |
| Revenue growth (YoY) | +6.36% | +50.73% |
| Net income (latest FY) | $6.63M | $-42.57M |
| Gross margin | 55.98% | 70.77% |
| Operating margin | 8.31% | -256.27% |
| Net margin | 4.62% | -264.44% |
| 52-week high | $15.47 | $8.95 |
| 52-week low | $7.29 | $4.80 |
| Distance from 52-week high | -7.24% | -28.72% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +28.92% | +74.61% |
| Average volume | 136.60K | 208.29K |
| Shares outstanding | 20.03M | 36.63M |
| Employees | 461 | 162 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INFU has outperformed PROF by 45.5 percentage points over the past year.
- InfuSystems is more profitable, keeping 4.6 cents of every revenue dollar as net income versus -264.4 cents for Profound Medical.
- Profound Medical grew revenue faster in its latest fiscal year (+50.73% vs +6.36%).
About InfuSystems
INFU stock →InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps and related products and services in the United States and Canada. It operates through two segments: Patient Services and Device Solutions.
Health Care · Medical/Dental Instruments · 461 employees
About Profound Medical
PROF stock →Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue.
Health Care · Medical/Dental Instruments · 162 employees
INFU vs PROF FAQ
Which is bigger, InfuSystems or Profound Medical?
InfuSystems (INFU) is larger, with a market capitalization of $287.48M compared with $233.68M for Profound Medical (PROF).
Which stock has performed better over the past year, INFU or PROF?
INFU returned +51.69% over the past 12 months, compared with +6.16% for PROF (price return, excluding dividends). Past performance does not predict future results.
Are InfuSystems and Profound Medical in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.